A stock-for-stock acquisition, supported by a $200M PIPE, creates a combined company advancing a differentiated BTK inhibitor pipeline for immune and CNS diseases. The deal targets large, underserved markets with parallel clinical programs and a cash runway into H2 2029.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.